U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 10-Q

ark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2012
TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 1-10526
UNITED-GUARDIAN, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware (State or Other Jurisdiction of Incorporation or Organization) 11-1719724 (I.R.S. Employer Identification No.)
230 Marcus Boulevard, Hauppauge, New York 11788 (Address of Principal Executive Offices)
(631) 273-0900 (Registrant's Telephone Number)
N/A (Former name, former address and former fiscal year, if changed since last report)

Yes 🗹

No □

filing requirements for the past 90 days.

· · · · · · · · · · · · · · · · · · ·	he registrant has submitted electronically and posted on its ve Data File required to be submitted and posted pursuant to
Rule 405 of Regulation S-T during the	preceding 12 months (or for such shorter period that the
registrant was required to submit and post	•
non-accelerated filer, or a smaller report	e registrant is a large accelerated filer, an accelerated filer, a ing company. See definitions of "large accelerated filer", company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer	П
Non-accelerated filer	☐ (Do not check if a smaller reporting company)
Accelerated filer	
Smaller reporting company	
Indicate by check mark whether t of the Exchange Act.)	the registrant is a shell company (as defined in Rule 12b-2
	Yes □ No Ø
Indicate the number of shares outst the latest practicable date:	anding of each of the issuer's classes of common stock, as of
4.596.439 shares of co	ommon stock, par value \$.10 per share

4,596,439 shares of common stock, par value \$.10 per share (as of May 1, 2012)

UNITED-GUARDIAN, INC. INDEX TO FINANCIAL STATEMENTS

Part I. FINANCIAL INFORMATION	<u>Page No.</u>
Item 1 - Condensed Financial Statements (unaudited unless otherwise indicated):	
Statements of Income - Three months ended March 31, 2012 and 2011	2
Statements of Comprehensive Income - Three months ended March 31, 2012 and 2011	3
Balance Sheets - March 31, 2012 (unaudited) and December 31, 2011 (audited)	4-5
Statements of Cash Flows - Three months ended March 31, 2012 and 2011	6
Notes to Condensed Financial Statements	7-11
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations	11-15
Item 3 - Quantitative and Qualitative Disclosures About Market Risk	15
Item 4 - Controls and Procedures	15-16
Part II. OTHER INFORMATION	
Item 1 - Legal Proceedings	16
Item 1A - Risk Factors	16
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds	16
Item 3 - Defaults Upon Senior Securities	16
Item 4 - Mine Safety Disclosures	16
Item 5 - Other Information	16
Item 6 - Exhibits	16
Signatures	17

Part I. FINANCIAL INFORMATION

ITEM 1. Condensed Financial Statements

UNITED-GUARDIAN, INC.

STATEMENTS OF INCOME

(UNAUDITED)

THREE MONTHS ENDED MARCH 31,

	<u>2012</u>	<u>2011</u>
Net sales	\$ <u>3,888,692</u>	\$ <u>3,642,049</u>
Costs and expenses: Cost of sales Operating expenses Total costs and expenses	1,539,840 602,863 2,142,703	1,460,590 <u>521,146</u> <u>1,981,736</u>
Income from operations	1,745,989	1,660,313
Other income: Investment income Gain (loss) on sale of asset Total other income Income before income taxes	69,591 2,750 72,341 1,818,330	71,323 (5,253) 66,070 1,726,383
Provision for income taxes	<u>589,700</u>	560,200
Net income	\$ <u>1,228,630</u>	\$ <u>1,166,183</u>
Earnings per common share (Basic and Diluted)	\$0.27	\$0.25
Weighted average shares – basic and diluted	<u>4,596,439</u>	<u>4,596,439</u>

See notes to condensed financial statements

STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

	THREE MONTHS ENDED MARCH 31,			
	<u>2012</u>	<u>2011</u>		
Net income	\$ <u>1,228,630</u>	\$ <u>1,166,183</u>		
Other comprehensive income:				
Unrealized gain on marketable securities during period	95,171	23,556		
Income tax expense related to other comprehensive income	32,987	8,163		
Other comprehensive income, net of tax	62,184	15,393		
Comprehensive income	\$ <u>1,290,814</u>	\$ <u>1,181,576</u>		

BALANCE SHEETS

<u>ASSETS</u>	MARCH 31, 2012 (UNAUDITED)	DECEMBER 31, 2011
Current assets:	(=====)	
Cash and cash equivalents	\$ 1,582,188	\$ 1,090,974
Marketable securities	10,883,539	9,295,755
Accounts receivable, net of allowance for doubtful accounts of \$18,000 at March 31, 2012 and December 31, 2011	1,529,393	1,653,440
Inventories (net)	1,256,575	1,467,434
Prepaid expenses and other current assets	167,258	163,034
Prepaid income taxes		78,613
Deferred income taxes Total current assets	<u>223,546</u> 15,642,499	<u>223,546</u> <u>13,972,796</u>
Property, plant and equipment:		
Land	69,000	69,000
Factory equipment and fixtures	3,740,393	3,694,379
Building and improvements	2,716,516	2,714,780
Waste disposal plant	133,532	133,532
Total property, plant and equipment	6,659,441	6,611,691
Less: Accumulated depreciation Total property, plant and equipment, net	5,404,609 1,254,832	<u>5,366,204</u> <u>1,245,487</u>
Other assets	28,254	<u>37,672</u>
TOTAL ASSETS	\$ <u>16,925,585</u>	\$ <u>15,255,955</u>

BALANCE SHEETS

(continued)

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:	MARCH 31, 2012 (UNAUDITED)	D	DECEMBER 31,
Accounts payable	\$ 127,506	\$	400,389
Accrued expenses	794,129		676,959
Income taxes payable Total current liabilities	501,542 1,423,177		1,077,348
Deferred income taxes	<u>97,565</u>		64,578
Stockholders' equity:			
Common stock \$.10 par value, authorized, 10,000,000 shares; 4,596,439 shares issued and outstanding at March 31, 2012 and December 31, 2011.	459,644		459,644
Accumulated other comprehensive loss	96,796		34,612
Retained earnings	14,848,403		13,619,773
Total stockholders' equity	15,404,843		14,114,029
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ <u>16,925,585</u>	\$	<u>15,255,955</u>

STATEMENTS OF CASH FLOWS

(UNAUDITED)

THREE MONTHS ENDED MARCH 31,

			WAITOITS	WAITOIT 51,		
		<u>2012</u>		<u>2011</u>		
Cash flows from operating activities:	•		•			
Net income	\$	1,228,630	\$	1,166,183		
Adjustments to reconcile net income to net cash						
provided by operating activities:		00.040		F7 000		
Depreciation and amortization		66,943		57,269		
Realized loss on sale of investments		6,489				
Realized (gain) loss on sale of asset		(2,750)		5,253		
Increase (decrease) in cash resulting from						
changes in operating assets and liabilities:						
Accounts receivable		124,047		(653,340)		
Inventories		210,859		153,680		
Prepaid expenses and other current assets		(4,224)		21,352		
Accounts payable		(272,883)		180,313		
Accrued expenses and taxes payable		697,325		492,354		
Net cash provided by operating activities		2,054,436		1,423,064		
Cash flows from investing activities:						
Acquisition of property, plant and equipment		(66,870)		(32,572)		
Proceeds from sales of assets		2,750		15,154		
Proceeds from sale of marketable securities		80,744				
Purchase of marketable securities		(1,579,846)		<u>(356,598</u>)		
Net cash used in investing activities		(1,563,222)		(374,016)		
Net increase in cash and cash equivalents		491,214		1,049,048		
Cash and cash equivalents at beginning of period		1,090,974		<u>1,514,589</u>		
Cash and cash equivalents at end of period	\$	<u>1,582,188</u>	\$	<u>2,563,637</u>		

NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

Nature of Business

United-Guardian, Inc. (the "Company") is a Delaware corporation that, through its Guardian Laboratories division, conducts research, product development, manufacturing and marketing of cosmetic ingredients and other personal care products, pharmaceuticals, medical and health care products and proprietary specialty industrial products.

2. Basis of Presentation

Interim financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation SX. In the opinion of management, all adjustments, consisting solely of normal recurring accruals, considered necessary for the fair presentation of financial statements for the interim periods have been included. The results of operations for the current period are not necessarily indicative of results that ultimately may be achieved for any other interim period or for the year ending December 31, 2012. The interim unaudited financial statements and notes thereto should be read in conjunction with the audited financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2011.

3. Stock-Based Compensation

The Company maintains a stock-based compensation plan for its employees and directors, which is more fully described in the Company's Annual Report on Form 10-K for the year ended December 31, 2011. The Company recognizes the fair value of all share-based payments to employees, including grants of employee stock options, as a compensation expense in the financial statements.

As of March 31, 2012, the Company had no share-based awards outstanding and exercisable and did not grant any options during the three months ended March 31, 2012.

As of March 31, 2012, there was no remaining unrecognized compensation cost related to the non-vested share-based compensation arrangements granted under the Company's plans.

The Company did not record any stock-based compensation expense during the three-month periods ended March 31, 2012 and 2011.

The Company did not receive any proceeds from the exercise of options during the three months ended March 31, 2012 and 2011.

4. Recent Accounting Pronouncements

In June 2011, FASB issued an amendment to the disclosure requirements for the presentation of comprehensive income. The amendment requires that all non-owner changes in stockholders' equity be presented either in a single continuous statement of comprehensive income or in two

separate but consecutive statements. This guidance is effective retrospectively for the interim periods and annual periods beginning after December 15, 2011. The Company adopted this amendment effective January 1, 2012. The adoption of this amendment did not have a material impact on the Company's results of operation.

5. Investments

The fair values of the Company's marketable securities are determined in accordance with GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by GAAP, which prioritizes the inputs used in measuring fair value as follows:

- Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
- Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially for the full term of the financial statement.
- Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following available-for-sale securities, which comprise all the Company's marketable securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs, which are quoted prices (unadjusted) for identical assets in active markets.

March 31, 2012	Cost	Fair Value	Jnrealized Gain (Loss)
Available for sale:		<u> </u>	
U.S. treasury and agencies: Maturities within 1 year	\$ 249,137	\$ 231,657	\$ <u>(17,480)</u>
Corporate bonds Maturities within 1 year Maturities after 1 year through 5 years Total corporate bonds	185,747 203,920 389,667	171,757 203,150 374,907	(13,990) (770) (14,760)
Fixed income mutual funds	9,841,477	10,002,617	<u>161,140</u>
Equity and other mutual funds	\$ 255,114 10,735,395	274,358	\$ 19,244 148,144

<u>December 31, 2011</u>				Onet Fair Value			Unrealized	
Available for sale:		<u>Cost</u>		<u>Fair Value</u>	<u>(</u>	Gain (Loss)		
U.S. treasury and agencies Maturities within 1 year	\$	249,137	\$	234,388	\$	(14,749)		
Corporate bonds: Mature within 1 year Maturities after 1 year through 5 years Total corporate bonds		267,251 203,920 471,171		247,719 195,899 443,618		(19,532) (8,021) (27,553)		
Fixed income mutual funds		8,268,624		8,372,216		103,592		
Equity and other mutual funds	\$	253,850 9,242,782	\$	245,533 9,295,755	\$	(8,317) 52,973		

Proceeds from the sale and redemption of marketable securities amounted to \$80,744 for the first quarter of 2012, and generated realized losses of \$6,489. There were no redemptions of marketable securities in the first quarter of 2011.

Investment income consisted principally of interest income from bonds and money market funds and dividend income from bond funds and mutual funds.

Marketable securities include investments in equity mutual funds, government securities and corporate bonds which are classified as "available-for-sale" securities and are reported at their fair values. Unrealized gains and losses on "available-for-sale" securities are reported as accumulated other comprehensive income (loss) in stockholders' equity, net of the related tax effects. Investment income is recognized when earned. Realized gains and loses on sales of investments are determined on a specific identification basis.

6. Inventories

	March 31, 2012	December 31, 2011
Inventories consist of the following:	<u>== :=</u>	<u>=0</u>
Raw materials and work in process	\$ 548,356	\$ 470,532
Finished products	708,219	996,902
·	\$ 1,256,575	\$ 1,467,434

Inventories are valued at the lower of cost or current market value. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out ("FIFO") method. Finished products inventories at March 31, 2012 and December 31, 2011 are stated net of a reserve of \$20,000 for slow moving and obsolete inventory.

7. Supplemental Financial Statement Information

For purposes of the Statements of Cash Flows, the Company considers all highly liquid investments purchased with an initial maturity of three months or less to be cash equivalents.

For the first quarter of 2012 there was a cash payment for taxes in the amount \$9,245, as compared with no payment in the first quarter of 2011. There were no payments for interest for the first quarters of 2012 and 2011.

Research and development expenses amounted to \$146,342 and \$127,271 for the first quarters of 2012 and 2011, respectively, and are included in operating expenses.

There were no dividends paid in the first quarters of 2012 and 2011.

8. Income Taxes

The Company's tax provision is based on its estimated annual effective tax rate. The Company continues to fully recognize its tax benefits, which are offset by a valuation allowance to the extent that it is more likely than not that the deferred tax assets will not be realized. As of December 31, 2011 and March 31, 2012, the Company did not have any unrecognized tax benefits.

The Company files consolidated Federal income tax returns in the United States with its inactive subsidiary, and separate income tax returns in New York State. The Company is subject to examination by the Internal Revenue Service and by New York State for years 2008 through 2011.

The Company's policy is to recognize interest and penalties as interest expense.

9. Comprehensive Income

Accumulated other comprehensive income comprises unrealized gains and losses on marketable securities net of the related tax effect.

10. Defined Contribution Plan

The Company sponsors a 401(k) defined contribution plan ("DC Plan") that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee's pay. Employees become fully vested in employer matching contributions after one year of employment. The Company accrued \$43,750 in contributions for each of the first quarters of 2012 and 2011. For the first quarters of 2012 and 2011 the Company did not make any discretionary contributions to the DC Plan.

11. Related Party Transactions

For the first quarter of 2012 the Company made no payments to Henry Globus, a former officer and director of the Company who passed away in December 2011, as compared with the first quarter of 2011, in which the Company paid him \$5,574. The payments were for consulting services in accordance with his employment termination agreement of 1988.

During the first quarter of 2011 the Company sold one of its vehicles, with a book value of \$20,407, to one of its Vice President's for \$15,154, the vehicle's fair market value, as part of his severance package. As a result, the Company recognized a loss of \$5,253.

12. Other Information

Accrued Expenses

	March 31,	I	December 31	,
	<u> 2012</u>		<u>2011</u>	
Accrued bonuses	\$ 300,000	\$	200,000	
Accrued distribution fees	193,904		191,171	
Payroll and related expenses	177,475		80,986	
Other	122,750		<u>204,802</u>	
	\$ <u>794,129</u>	\$	<u>676,959</u>	

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENTS

Statements made in this Form 10-Q, which are not purely historical, are forward-looking statements with respect to the goals, plans, objectives, intentions, expectations, financial condition, results of operations, future performance and business of the Company. Forward-looking statements may be identified by the use of such words as "believes," "may," "will," "should," "intends," "plans," "estimates," or "anticipates" or other similar expressions.

Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond our control) could cause actual results to differ materially from those set forth in the forward-looking statements. In addition to those specific risks and uncertainties set forth in the Company's reports currently on file with the SEC, some other factors that may affect the future results of operations of the Company are: the development of products that may be superior to those of the Company; changes in the quality or composition of the Company's products; lack of market acceptance of the Company's products; the Company's ability to develop new products; general economic or industry conditions; intellectual property rights; changes in interest rates; new legislation or regulatory requirements; conditions of the securities markets; the Company's ability to raise capital; changes in accounting principles, policies or guidelines; financial or political instability; acts of war or terrorism; and other economic, competitive, governmental, regulatory and technical factors that may affect the Company's operations, products, services and prices.

Accordingly, results actually achieved may differ materially from those anticipated as a result of such forward-looking statements, and those statements speak only as of the date they are made. The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.

OVERVIEW

The Company is a Delaware corporation that conducts research, product development, manufacturing and marketing of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products. All of the products that the Company manufactures, with the exception of its RENACIDIN IRRIGATION[®] ("RENACIDIN"), are produced at its facility in Hauppauge, New York, and are marketed through marketing partners,

distributors, wholesalers, direct advertising, mailings, and trade exhibitions. Its most important personal care product line is its LUBRAJEL[®] line of water-based moisturizing and lubricating gels. It also sells two pharmaceutical products for urological uses. Those products are sold primarily through the major drug wholesalers, which in turn sell the products to pharmacies, hospitals, nursing homes and other long-term care facilities, and to government agencies, primarily the Veteran's Administration.

The Company's pharmaceutical products are distributed primarily in the United States. Its personal care products are marketed worldwide by five marketing partners, of which Ashland Specialty Ingredients ("ASI") (formerly International Specialty Products, Inc) purchases the largest volume of products from the Company. Approximately one-half of the Company's products are sold, either directly or through the Company's marketing partners, to end users located outside of the United States.

While the Company does have competition in the marketplace for some of its products, many of its products are either unique in their field or have some unique characteristics, and therefore are not in direct competition with the products of other pharmaceutical, specialty chemical, or health care companies. Many of the Company's products are manufactured using patented or proprietary processes. The Company's research and development department is actively working on the development of new products to expand the Company's line of personal care and performance products.

The Company recognizes revenue when products are shipped, title and risk of loss pass to the customers, persuasive evidence of a sales arrangement exists, and collections are reasonably assured. An allowance for returns, based on historical experience, is taken as a reduction of sales within the same period the revenue is recognized.

The Company has been issued many patents and trademarks and intends, whenever possible, to make efforts to obtain patents in connection with its product development program.

CRITICAL ACCOUNTING POLICIES

As disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011, the discussion and analysis of the Company's financial condition and results of operations are based on its financial statements, which have been prepared in conformity with U.S. generally accepted accounting principles. The preparation of those financial statements required the Company to make estimates and assumptions that affect the carrying value of assets, liabilities, revenues and expenses reported in those financial statements. Those estimates and assumptions can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company's most critical accounting policies relate to revenue recognition, concentration of credit risk, inventory, patents, and income taxes. Since December 31, 2011, there have been no significant changes to the assumptions and estimates related to those critical accounting policies.

The following discussion and analysis covers material changes in the financial condition of the Company since the year ended December 31, 2011, and a comparison of the results of operations for the three months ended March 31, 2012 and March 31, 2011. This discussion and analysis should be read in conjunction with "Management's Discussion and Analysis or Plan of Operation" included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011.

RESULTS OF OPERATIONS

Sales

Net sales for the first quarter of 2012 increased by \$246,643 (6.8%) as compared with the first quarter of 2011. The change in net sales for the three-month period ended March 31, 2012 was primarily attributable to sales of the Company's products, as discussed below.

- (a) **Personal care products:** For the first quarter of 2012 the Company's gross sales of personal care products increased by \$125,653 (5.0%) when compared with the same period in 2011. This increase was due to an increase of \$141,324 (6.8%) in sales to the Company's largest marketing partner for the first quarter of 2012 when compared with the same period in 2011. The Company believes that the overall increase in personal care product sales was due to a number of factors, including an increase in demand for the Company's products, the replenishment of low inventory levels of certain products by the Company's largest marketing partner, and the timing of customer orders.
- (b) **Pharmaceuticals:** Gross sales of pharmaceuticals increased by \$395,014 (138.9%) in the first quarter of 2012 compared with the same period in 2011. The increase was primarily due to increased sales of RENACIDIN, which had normal production and availability in the first quarter of 2012 compared with limited availability in the first quarter of 2011. The limited availability in the first quarter of 2011 was due to the temporary curtailment of production by the Company's sole supplier of RENACIDIN from late 2010 until early 2011, due to regulatory issues unrelated to RENACIDIN. There were no such production issues in the first quarter of 2012.
- (c) Medical (non-pharmaceutical) products: Gross sales of the Company's medical products decreased \$242,131 (26.9%) for the first quarter of 2012 when compared with the same period in 2011. The Company believes the decrease was primarily due to the timing of customer orders.
- (d) **Industrial and other products:** Sales of the Company's industrial products, as well as other miscellaneous products, decreased by \$7,230 (25.1%) for the first quarter of 2012 compared with the same period in 2011.

In addition to the above changes in sales, net sales allowances increased by \$24,663 (41.6%) for the first quarter of 2012 when compared with the same period in 2011. This increase was primarily due to an increase in fees paid to the Veterans' Administration.

Cost of Sales

Cost of sales as a percentage of sales decreased slightly to 39.6% for the first quarter of 2012 from 40.1% for the first quarter in 2011. This was due to decreases in payroll, utilities, and insurance costs.

Operating Expenses

Operating expenses consist of selling, general, and administrative expenses. Operating expenses increased \$81,717 (15.7%) for the first quarter of 2012 compared with the first quarter of 2011. This increase was primarily attributable to increases in advertising, payroll and payroll related expenses, and real estate taxes. Real estate taxes were higher due to a refund that we received in the first quarter of 2011, which offset some of the real estate taxes. There was no such refund in the first quarter of 2012.

Other Income

Other income increased \$6,271 (9.5%) for the first quarter 2012 when compared with the comparable period in 2011. This was the result of an increase in realized gains from the sale of Company assets.

Provision for Income Taxes

The provision for income taxes increased by \$29,500 (5.3%) for the first quarter of 2012 when compared with the same period in 2011. This increase is mainly due to an increase in net income from operations before taxes of \$91,947 (5.3%) in 2012 when compared with 2011.

The Company's effective income tax rate was approximately 33.0% for the first quarter of 2012 and 2011, and is expected to remain consistent for the current fiscal year.

LIQUIDITY AND CAPITAL RESOURCES

Working capital increased by \$1,323,874 to \$14,219,322 at March 31, 2012 from \$12,895,448 at December 31, 2011. The increase in working capital is primarily due to an increase in marketable securities. The current ratio decreased to 11.0 to 1 at March 31, 2012 from 13.0 to 1 at December 31, 2011. The decrease in the current ratio was primarily due to the effect of an increase in income taxes payable.

During the three-month period ended March 31, 2012, the average period of time that an account receivable was outstanding was approximately 37 days. The average period of time that an account receivable was outstanding during the three-month period ended March 31, 2011 was 35 days. The increase was mainly due to a few customers who were paying more slowly than normal during the three-month period ended March 31, 2012.

The Company believes that its working capital is and will continue to be sufficient to support its operating requirements for at least the next twelve months. The Company does not expect to incur any significant capital expenditures for the remainder of 2012.

The Company generated cash from operations of \$2,054,436 and \$1,423,064 for the three months ended March 31, 2012 and March 31, 2011, respectively. The increase in cash was primarily due to an increase in accrued expenses and taxes payable, and a decrease in accounts receivable.

Cash used in investing activities for the three-month period ended March 31, 2012 was \$1,563,222, while cash used in investing activities for the three-month period ending March 31, 2011 was \$374,016. This decrease in cash was primarily due to an increase in the amount of marketable securities purchased in the first quarter of 2012 compared with the first quarter of 2011.

There was no cash used in financing activities for the first quarters of 2012 and 2011.

The Company expects to continue to use its cash to make dividend payments, to purchase marketable securities, and to take advantage of other opportunities that are in the best interests of the Company, should they arise.

RECENT ACCOUNTING PRONOUNCEMENTS

Please see Note 4 to the Financial Statements for a description of recent accounting pronouncements, including the expected dates of adoption and the anticipated impact on the financial statements.

OFF-BALANCE SHEET ARRANGEMENTS

The Company has no off-balance sheet transactions that have, or are reasonably likely to have, a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

The information to be reported under this item is not required of smaller reporting companies.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

The information to be reported under this item is not required of smaller reporting companies.

Item 4. CONTROLS AND PROCEDURES

(a) DISCLOSURE CONTROLS AND PROCEDURES

The Company's management, including its Principal Executive Officer and Principal Financial Officer, has evaluated the design, operation, and effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (the "Exchange Act"). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon the evaluation performed by the Company's management. including its Principal Executive Officer and Principal Financial Officer, it was determined that, as of the end of the period covered by this quarterly report, the Company's disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed in the reports filed or submitted pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Company's management, including its Principal Executive Officer and Principal Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding disclosures.

(b) CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

The Company's Principal Executive Officer and Principal Financial Officer have determined that, during the period covered by this quarterly report, there were no changes in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. They have also concluded that there were no significant changes in the Company's internal controls after the date of the evaluation.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

NONE

ITEM 1A. RISK FACTORS

The information to be reported under this item is not required of smaller reporting companies.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

NONE

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

NONE

ITEM 4. MINE SAFETY DISCLOSURES

NONE

ITEM 5. OTHER INFORMATION

NONE

ITEM 6. EXHIBITS

- 31.1 Certification of Kenneth H. Globus, President and Principal Executive Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 31.2 Certification of Robert S. Rubinger, Chief Financial Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32 Certifications of Principal Executive Officer and Chief Financial Officer of the Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

UNITED-GUARDIAN, INC. (Registrant)

By: <u>/S/ KENNETH H. GLOBUS</u> Kenneth H. Globus President

By: <u>/S/ ROBERT S. RUBINGER</u>
Robert S. Rubinger
Chief Financial Officer

Date: May 8, 2012